Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Rabewel LS
Rabewel LS is a scientifically formulated combination of Rabeprazole and Levosulpiride, designed for effective management of gastroesophageal reflux disease (GERD), functional dyspepsia, and acid-peptic disorders. This dual-action therapy ensures symptom relief by reducing acid secretion and improving gastric motility, enhancing digestive health.
Uses of Rabewel LS
Treatment of GERD and acid reflux disease
Management of gastritis, peptic ulcers, and non-ulcer dyspepsia
Prevention of gastric damage caused by NSAIDs
Improvement of delayed gastric emptying and motility disorders
Benefits of Rabewel LS
Effective Acid Control: Rabeprazole provides long-lasting gastric acid suppression.
Enhanced Gastric Motility: Levosulpiride regulates gut movement, reducing bloating and indigestion.
Dual Mechanism: Ensures comprehensive relief from reflux, heartburn, and dyspepsia.
Improved Patient Compliance: Well-tolerated with minimal side effects for long-term use.
Mechanism of Action of Rabewel LS
Rabeprazole: Inhibits the H+/K+ ATPase enzyme, blocking acid secretion at the gastric parietal cells, ensuring prolonged acid suppression.
Levosulpiride: Acts as a dopamine D2 receptor antagonist, enhancing gastrointestinal motility and preventing reflux by increasing lower esophageal sphincter tone.